This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Results demonstrate a substantial therapeutic advantage for deep and widespread stimulation using Brainsway’s proprietary ADHD coil over superficial stimulation with a standard figure-8 coil
Brainsway® Ltd. (TASE: BRIN), a leader in non-invasive brain stimulation, is pleased to announce final results from a phase II clinical study investigating the efficacy of Deep transcranial magnetic stimulation (Deep TMS) using a specialized electromagnetic coil developed for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. The study was conducted at the Soroka University Medical Center in Beer Sheva, Israel, in collaboration with the Ben Gurion University, and was led by Principal Investigators Dr. Hadar Shalev and Prof. Abraham Zangen.
The study included 53 adult ADHD patients, who were randomly assigned to one of three treatment groups in a double-blind manner (treatment allocation was concealed from both investigator and patient). Each patient was randomized to receive 15 treatments over 3 weeks (5 daily treatments a week) of either Deep TMS using either a specialized coil developed by Brainsway for deep stimulation of the right frontal lobe (Brainsway’s proprietary H6-Coil), standard TMS using a figure-8 TMS coil which stimulates only the surface of the right frontal lobe, or sham TMS. The results are based on the 42 participants that concluded the treatment period, as 11 patients left the study early – 10 of them left due to reasons unrelated to the device or procedure, and one patient in the standard TMS treatment group left due to the occurrence of a seizure.
Treatment effects were assessed using standard ADHD rating scales, a computerized task for objective evaluation of attentional functioning, and electroencephalography (EEG) to record electrical activity in the patients’ brains.
The primary efficacy outcome measure was the change in scores on the Conner’s Adult ADHD Rating Scale (CAARS) self-report questionnaire. In the Deep TMS group, a significant average improvement of 8.25 points (p=0.0001) was observed in total CAARS scores compared with pre-treatment baseline values. However, in the sham TMS group, there was an insignificant change (p=0.33) of 1.86 points only. In the standard TMS group, the change was only 2.85 points (p=0.15). Similar results were observed on all ADHD symptom subscales.
The percentage of patients who responded to the treatment (who showed a reduction of 30% or more in the CAARS scale) was 33% in the Deep TMS group, 8% in the sham group, and 15% in the standard TMS group).
According to the Principal Investigators, the results of this study demonstrate that Deep TMS using Brainsway’s specialized ADHD H-Coil is safe, and may be used to effectively treat ADHD. The results of the study also demonstrate a substantial therapeutic advantage for deep and widespread stimulation using Brainsway’s proprietary ADHD coil over superficial stimulation with a standard figure-8 coil.
Brainsway is dedicated to research, development and marketing of a medical device for non-invasive treatment of prevalent brain disorders. The company’s device is based on unique groundbreaking Deep TMS technology, which can be used to reach deep brain regions and generate neural stimulation or inhibition. The company’s systems are sold worldwide, with FDA and CE clearances, as well as medical reimbursement covering approximately 70% of US population. The company currently focuses on commercialization, and on increasing penetration of the US market for treatment of severe depression.
For more information please contact:
Hadar Friedman Zik
Investor Relations Ltd.